Immune Therapeutics Statement on the Death of Christopher Pearce, Founder and Chief Operating Officer
December 12 2016 - 9:00AM
Marketwired
Immune Therapeutics Statement on the Death of Christopher
Pearce, Founder and Chief Operating Officer
ORLANDO, FL-(Marketwired - Dec 12, 2016) - Immune Therapeutics,
Inc. (OTCQB: IMUN) ("Immune Therapeutics"), a clinical-stage
biotech company providing immunotherapy solutions for the treatment
of autoimmune disease and cancer, today announced with immense
sadness the passing of Christopher Pearce, one of the founders of
Immune Therapeutics and its chief operating officer. Mr. Pearce
passed away after a 10-year battle with cancer.
"This is a very sad time for all of us at Immune Therapeutics,"
said Noreen Griffin, chief executive officer. "Chris was a great
friend, respected colleague and a valuable member of our executive
management team. We will miss him deeply. We extend our sympathies
to his family and friends at this difficult time."
About Immune Therapeutics:
Immune Therapeutics is a biotechnology company working to combat
chronic, life-threatening diseases through the activation and
modulation of the body's immune system using its patented
immunotherapies with a focus of providing such therapies in
emerging nations. Its products and immunotherapy technologies are
designed to harness the power of the immune system to improve the
treatment of cancer, infections such as HIV/AIDS, chronic
inflammatory and autoimmune diseases.
Immune Therapeutics' proprietary technology, therapies and
patents include the treatment of a wide range of cancers. Its most
advanced clinical programs involve immunotherapy with
met-enkephalin (MENK) (sometimes referred to as opioid growth
factor) and its Low Dose Naltrexone product (LDN) or Lodonal, which
have been shown to stimulate the immune system even in patients
with advanced cancer.
Contact Amato and Partners, LLC Investors Relations Counsel 90
Park Avenue. 17th Floor New York, NY 10016
admin@amatoandpartners.com
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024